4.6 Article

Transcranial direct current stimulation in treatment resistant depression: A randomized double-blind, placebo-controlled study

Journal

BRAIN STIMULATION
Volume 5, Issue 3, Pages 242-251

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.brs.2011.08.005

Keywords

noninvasive brain stimulation; prefrontal cortex; antidepressant treatment; major depression; cognition

Funding

  1. Brainsway
  2. Aspect Medical systems
  3. Lundbeck
  4. UCB Schwarz Pharma
  5. GlaxoSmithKline
  6. AstraZeneca
  7. Bristol-Myers Squibb
  8. Eli Lilly
  9. Eisai
  10. Janssen Cilag
  11. Merck
  12. Novartis
  13. Organon
  14. Pfizer
  15. Sanofi Aventis
  16. Sepracor
  17. Servier
  18. Wyeth

Ask authors/readers for more resources

Background Anodal transcranial direct current stimulation (tDCS) of the prefrontal cortex has been proposed as therapeutic intervention in major depression. According to clinical needs, this study addresses the question whether tDCS is effective in treatment resistant major depressive episodes. Methods Twenty-two patients with a major depressive episode were randomly assigned to a cross-over protocol comparing tDCS and placebo stimulation add-on to a stable antidepressant medication. The parameters of active tDCS were: 1 or 2 mA for 20 minutes/day, anode over the left dorsolateral prefrontal cortex, cathode over the contralateral supraorbital region. Active and placebo tDCS was applied for 2 weeks using indistinguishable DC stimulators. Patients, raters, and operators were blinded to treatment conditions. Results There was no significant difference in depression scores after 2 weeks of real compared with 2 weeks of sham tDCS. Scores on the Hamilton Depression Rating Scale were reduced from baseline by 14.7% for active tDCS and 10% for placebo tDCS. In contrast, subjective mood ratings showed an increase in positive emotions after real tDCS compared with sham tDCS. Conclusions Anodal tDCS, applied for 2 weeks, was not superior to placebo treatment in patients with treatment resistant depression. However, secondary outcome measures are pointing to a positive effect of tDCS on emotions. Therefore, modified and improved tDCS protocols should be carried out in controlled pilot trials to develop tDCS towards an efficacious antidepressant intervention in therapy-resistant depression. (C) 2012 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available